Clinical Trial Update: Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating letrozole in postmenopausal women with ER-positive and/or PR-positive stage II-IIIB breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEMARA (letrozole)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED